Abstract
Therapy for those with relapsed or refractory acute myeloid leukemia is suboptimal. Studies have suggested that timed sequential salvage combination cytotoxic chemotherapy may be particularly useful for that indication. We report here a series of ten such adult patients treated sequentially at a single center with EMA (cytarabine 500 mg/m2/day as continuous infusion on days 1–3 and days 8–10, mitoxantrone 12 mg/m2/day on days 1–3, and etoposide 200 mg/m2/day as continuous infusion on days 8–10). The overall complete remission rate was 40% (including 3 of 4 of those with relapsed disease), but use of this regimen was associated with prolonged cytopenia and a high rate of infectious adverse events. Even with the availability of modern infectious prophylaxis and therapies, the EMA regimen is likely best reserved for those with relapsed disease treated with curative intent prior to an allogeneic hematopoietic cell transplant.
Article PDF
Avoid common mistakes on your manuscript.
References
Dohner, H, Estey, E, Grimwade, D, Amadori, S, Appelbaum, FR, Buchner, T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129;424–47.
DeStefano, CB, Hourigan, CS. Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice. Ther Adv Hematol 2018;9;109–21.
DiNardo, CD, Perl, AE. Advances in patient care through increasingly individualized therapy. Nat Rev Clin Oncol 2019;16;73–4.
Lai, C, Karp, JE, Hourigan, CS. Precision medicine for acute myeloid leukemia. Expert Rev Hematol 2016;9;1–3.
Walter, RB, Othus, M, Burnett, AK, Lowenberg, B, Kantarjian, HM, Ossenkoppele, GJ, et al. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia 2015;29;312–20.
Culos, K, Byrne, M. Salvage therapy after allogeneic hematopoietic cell transplantation: targeted and low-intensity treatment options in myelodysplastic syndrome and acute myeloid leukemia. Clin Hematol Int 2019;1;94–100.
Othus, M, Appelbaum, FR, Petersdorf, SH, Kopecky, KJ, Slovak, M, Nevill, T, et al. Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 2015;21;559–64.
Horibata, S, Gui, G, Lack, J, DeStefano, CB, Gottesman, MM, Hourigan, CS. Heterogeneity in refractory acute myeloid leukemia. Proc Natl Acad Sci USA 2019;116;10494–503.
Ramos, NR, Mo, CC, Karp, JE, Hourigan, CS. Current approaches in the treatment of relapsed and refractory acute myeloid leukemia. J Clin Med 2015;4;665–95.
Vaughan, WP, Karp, JE, Burke, PJ. Long chemotherapy-free remissions after single-cycle timed-sequential chemotherapy for acute myelocytic leukemia. Cancer 1980;45;859–65.
Karp, JE, Donehower, RC, Enterline, JP, Dole, GB, Fox, MG, Burke, PJ. In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia. Blood 1989;73;24–30.
Norsworthy, KJ, DeZern, AE, Tsai, HL, Hand, WA, Varadhan, R, Gore, SD, et al. Timed sequential therapy for acute myelogenous leukemia: results of a retrospective study of 301 patients and review of the literature. Leuk Res 2017;61;25–32.
Archimbaud, E, Leblond, V, Michallet, M, Cordonnier, C, Fenaux, P, Travade, P, et al. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. Blood 1991;77;1894–900.
Thomas, X, Fenaux, P, Dombret, H, Delair, S, Dreyfus, F, Tilly, H, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial). Leukemia 1999;13; 1214–20.
Wong, HY, Sung, AD, Lindblad, KE, Sheela, S, Roloff, GW, Rizzieri, D, et al. Molecular measurable residual disease testing of blood during AML cytotoxic therapy for early prediction of clinical response. Front Oncol 2018;8;669.
Baden, LR, Swaminathan, S, Angarone, M, Blouin, G, Camins, BC, Casper, C, et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 2016;14; 882–913.
Sheela, S, Ito, S, Strich, JR, Manion, M, Montemayor-Garcia, C, Wang, HW, et al. Successful salvage chemotherapy and allogeneic transplantation of an acute myeloid leukemia patient with disseminated Fusarium solani infection. Leuk Res Rep 2017; 8;4–6.
Dohner, H, Weisdorf, DJ, Bloomfield, CD. Acute myeloid leukemia. N Eng J Med 2015;373;1136–52.
Roboz, GJ, Rosenblat, T, Arellano, M, Gobbi, M, Altman, JK, Montesinos, P, et al. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. J Clin Oncol 2014; 32;1919–26.
Litzow, MR, Wang, XV, Carroll, MP, Karp, JE, Ketterling, RP, Zhang, Y, et al. A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. Am J Hematol 2019;94;111–17.
Schmid, C, Schleuning, M, Schwerdtfeger, R, Hertenstein, B, Mischak-Weissinger, E, Bunjes, D, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006;108;1092–9.
Duléry, R, Ménard, A-L, Chantepie, S, El-Cheikh, J, François, S, Delage, J, et al. Sequential conditioning with Thiotepa in T Cell-replete hematopoietic stem cell transplantation for the treatment of refractory hematologic malignancies: comparison with matched related, Haplo-mismatched, and unrelated donors. Biol Blood Marrow Transplant 2018;24;1013–21.
Author information
Authors and Affiliations
Corresponding author
Additional information
Peer review under responsibility of the International Academy for Clinical Hematology
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
Popescu, B., Sheela, S., Thompson, J. et al. Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia. Clin Hematol Int 2, 27–31 (2020). https://doi.org/10.2991/chi.d.191128.001
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/chi.d.191128.001